Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Polycythemia Vera: Considerations in Hematocrit Control

September 29th 2016

Patient Selection for Treatment of Polycythemia Vera

September 29th 2016

Assessing Risk in Polycythemia Vera

September 29th 2016

Understanding Polycythemia Vera

September 29th 2016

Unmet Needs in Myelofibrosis

September 29th 2016

Therapeutic Response with JAK Inhibition in Myelofibrosis

September 29th 2016

Cytopenia-Related Considerations in Myelofibrosis

September 29th 2016

Optimal Timing of JAK Inhibition in Myelofibrosis

September 29th 2016

Role for JAK Inhibition in Myelofibrosis

September 29th 2016

Myelofibrosis: Considerations for Transplant or Surgery

September 29th 2016

When to Initiate Therapy in Myelofibrosis

September 29th 2016

Practical Risk Assessment in Myelofibrosis

September 29th 2016

Mutations, Diagnosis, and Prognosis in Myelofibrosis

September 29th 2016

Understanding Drivers of Progression in Myelofibrosis

September 29th 2016

KTE-C19 Induces Complete Remissions in Phase II Lymphoma Study

September 27th 2016

Treatment with KTE-C19 demonstrated an objective response rate of 79% and a complete remission rate of 52% for patients with aggressive, chemorefractory non-Hodgkin's lymphoma.

FDA Approval Sought for Ibrutinib in Marginal Zone Lymphoma

September 27th 2016

A supplemental new drug application has been submitted to the FDA for the use of ibrutinib as a treatment for patients with marginal zone lymphoma.

Anti-CD19 CAR T-Cell Therapy Induces Significant Remission Rates in B-Cell ALL

September 19th 2016

Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.

Individualizing Therapy for Patients With Waldenstrom's Macroglobulinemia

September 16th 2016

Improved understanding of Waldenström's macroglobulinemia and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy

CAR T-Cell Therapy Continues to Show Promise in Non-Hodgkin Lymphoma

September 13th 2016

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

Imetelstat Future Unclear in MDS

September 13th 2016

The future of imetelstat as a treatment for patients with myelodysplastic syndromes is uncertain following an update on 2 clinical trials.